Valuation: Pelthos Therapeutics Inc.

Market Cap 35.99M 32.23M 29.65M 26.86M 50.21M 3.42B 51.15M 354M 142M 1.8B 135M 132M 5.67B P/E 2026 *
-0.52x
P/E 2027 * -2.42x
Enterprise Value 35.99M 32.23M 29.65M 26.86M 50.21M 3.42B 51.15M 354M 142M 1.8B 135M 132M 5.67B EV / Sales 2026 *
0.58x
EV / Sales 2027 * 0.33x
Free-Float
49.95%
Yield 2026 *
-
Yield 2027 * -
1 day-43.17%
1 week-44.71%
1 month-55.26%
3 months-67.20%
6 months-62.40%
Current year-69.68%
1 week 9.02
Extreme 9.02
20.5
1 month 9.02
Extreme 9.02
22.95
Current year 9.02
Extreme 9.02
30.99
1 year 9.02
Extreme 9.02
37.5
3 years 4.5
Extreme 4.5
60
5 years 4.5
Extreme 4.5
60
10 years 4.5
Extreme 4.5
60
Date Insider Type Main position Quantity % Market Cap. Importance
10/2/26 Sell

Director

-558 0.0161%
10/2/26 Sell

Chairman

-797 0.0229%
10/2/26 Sell

Director

-786 0.0226%
Change 5-day change 1-year change 3-year change Capi.($)
-43.17%-44.71%-71.52% - 35.99M
+3.19%+11.31%+64.28%+155.91% 1,263B
-0.73%+3.56%+44.65%+84.17% 658B
+1.41%+3.24%+35.25%+108.88% 521B
+0.42%+3.20%+55.81%+72.50% 391B
+2.18%+2.93%+73.90%+45.59% 369B
+1.12%+4.52%+34.76%+58.24% 307B
+6.96%+8.86%+11.95%+36.20% 290B
+1.15%+6.09%+56.15%+82.25% 252B
+3.06%+9.38%+42.48%+117.32% 212B
Average -2.44%+0.84%+34.77%+84.56% 426.2B
Weighted average by Cap. +2.01%+6.60%+50.51%+100.44%

Financials

2026 *2027 *
Net sales 62.36M 55.85M 51.37M 46.55M 87.01M 5.92B 88.64M 613M 246M 3.11B 234M 229M 9.82B 108M 97.08M 89.3M 80.91M 151M 10.29B 154M 1.06B 427M 5.41B 407M 398M 17.07B
Net income -65.56M -58.72M -54.01M -48.94M -91.48M -6.23B -93.19M -644M -259M -3.27B -246M -241M -10.33B -28.76M -25.76M -23.69M -21.47M -40.13M -2.73B -40.88M -283M -113M -1.44B -108M -106M -4.53B
Net Debt - -
Projected Income Statement - Annual - Pelthos Therapeutics Inc.
Logo Pelthos Therapeutics Inc.
Pelthos Therapeutics Inc. is a biopharmaceutical company focused on commercializing therapeutic products for unmet patient needs. The Company's lead product, ZELSUVMI (berdazimer) topical gel, 10.3%, is used in the treatment of molluscum contagiosum infections (molluscum) in adults and pediatric patients one year of age and older. In addition to ZELSUVMI, the Company has a pipeline of product candidates that utilize its proprietary nitric oxide-based technology platform, NITRICIL. The Company’s product Xepi is a quinolone antimicrobial indicated for the topical treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients two months of age and older. Its NaV 1.7 is a clinical-stage assets which selectively target the sodium ion-channel. The Company also Xeglyze, which is a is a pediculicide indicated for the topical treatment of head lice infestation in patients six months of age and older.
Employees
92
Date Price Change Volume
26-10-30 US$9.400 -43.17% 242,032
26-10-29 US$16.54 +5.08% 14,741
26-10-28 US$15.74 +8.55% 49,702
26-10-27 US$14.50 -4.61% 73,232
26-10-26 US$15.20 -10.59% 22,810
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Pelthos Therapeutics Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
9.400USD
Average target price
49.57USD
Spread / Average Target
+427.36%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Pelthos Therapeutics Inc.
  1. Stock Market
  2. Stocks
  3. PTHS Stock